# EDGAR Filing Document

**Accession Number:** 0001173281
**File Stem:** 0000000000-23-002290
**Filing Date:** 2023-3
**Character Count:** 7500
**Document Hash:** 9ca738e7660952815d9a70eb46d9a92e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002290.hdr.sgml**: 20230418

**ACCESSION NUMBER**: 0000000000-23-002290

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230308

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuBase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001173281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 465622433
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 350 TECHNOLOGY DRIVE
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15219
- **BUSINESS PHONE:** 412-763-3350

**MAIL ADDRESS:**
- **STREET 1:** 350 TECHNOLOGY DRIVE
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15219

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ohr Pharmaceutical Inc
- **DATE OF NAME CHANGE:** 20090819

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BBM HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20070402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRIME RESOURCE INC
- **DATE OF NAME CHANGE:** 20020513
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001410578-22-003576

## Text-Extract

```

United States securities and exchange commission logo

                              March 8, 2023

       Todd Branning
       Chief Financial Officer
       NeuBase Therapeutics, Inc.
       350 Technology Drive
       Pittsburgh, PA 15219

                                                        Re: NeuBase
Therapeutics, Inc.
                                                            Form 10-K for the
Year Ended September 30, 2022
                                                            Filed December 21,
2022
                                                            File No. 1-35963

       Dear Todd Branning:

              We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comment.

              Please respond to this comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to this comment, we may have additional comments.

       Form 10-K for the Year Ended September 30, 2022

       Management's Discussion and Analysis of Financial Condition and Results
of Operations, page
       89

   1.                                                   Given the significant
fluctuations in research and development expense during the years
                                                        presented as well as in
the subsequent interim period, please revise your future filings to
                                                        disclose the drivers of
the changes. As part of your response, address the following:
                                                            To the extent
possible, quantify the impact of your October 2022 restructuring and
                                                             refocusing of
development projects on the amounts incurred.
                                                            Disclose the costs
incurred during each period presented for each of your key
                                                             research and
development projects. If you do not track your research and
                                                             development costs
by project, please disclose that fact and explain why you do not
                                                             maintain and
evaluate research and development costs by project. Provide other
                                                             quantitative or
qualitative disclosure that provides more transparency as to the type of
                                                             research and
development expenses incurred (i.e. by nature or type of expense) which
                                                             should reconcile
to total research and development expense on the Statements of
 Todd Branning
NeuBase Therapeutics, Inc.
March 8, 2023
Page 2
              Operations.

       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       You may contact Jenn Do at (202) 551-3743 or Kevin Vaughn at (202)
551-3494 with
any questions.

FirstName LastNameTodd Branning                           Sincerely,
Comapany NameNeuBase Therapeutics, Inc.
                                                          Division of
Corporation Finance
March 8, 2023 Page 2                                      Office of Life
Sciences
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 8, 2023

Todd Branning
Chief Financial Officer
NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219

**Re: NeuBase Therapeutics, Inc.**

**Form 10-K for the Year Ended September 30, 2022**

**Filed December 21, 2022**

**File No. 1-35963**

Dear Todd Branning:

We have limited our review of your filing to the financial statements and related disclosures and have the following comment.

Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 10-K for the Year Ended September 30, 2022

Management's Discussion and Analysis of Financial Condition and Results of Operations, page 89

1. Given the significant fluctuations in research and development expense during the years presented as well as in the subsequent interim period, please revise your future filings to disclose the drivers of the changes. As part of your response, address the following:
- To the extent possible, quantify the impact of your October 2022 restructuring and refocusing of development projects on the amounts incurred.
- Disclose the costs incurred during each period presented for each of your key research and development projects. If you do not track your research and development costs by project, please disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. by nature or type of expense) which should reconcile to total research and development expense on the Statements of

Todd Branning
NeuBase Therapeutics, Inc.
March 8, 2023
Page 2

Operations.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Jenn Do at (202) 551-3743 or Kevin Vaughn at (202) 551-3494 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences